Descripción de la empresa
Maze Therapeutics, Inc. operates as a clinical stage biopharmaceutical company dedicated to developing small molecule precision medicines specifically for the treatment of kidney and metabolic diseases within the United States. The firm functions within the broader Healthcare sector and the specialized Biotechnology industry, positioning itself to leverage significant research and development capabilities aimed at addressing unmet medical needs in these therapeutic areas. As of the latest reporting data, the company holds a market capitalization of $1.41 billion and employs a workforce of 141 individuals to advance its pipeline of novel therapies. The valuation indicates that the market values the company at a substantial level relative to its current financial outputs, a common characteristic for early-stage biotechnology firms where future potential outweighs current profitability. However, the absence of reported revenue in the trailing twelve months suggests the company is still in a phase of heavy investment in clinical trials and product development rather than commercial sales, which defines its current operational scale and strategic focus on bringing MZE829 and other lead programs to market.
Salud financiera
The company reported a net income of $-131,120,000 for the trailing twelve months, while its revenue and EBITDA figures are not available in the provided data, reflecting the typical loss-making nature of clinical stage biotechs where costs vastly exceed current sales. The significant negative net income compared to the lack of revenue highlights an aggressive cost structure driven by high R&D expenditures and operational expenses necessary to advance drug candidates through clinical phases. Free cash flow stands at $-72,523,872, indicating that the company is burning through cash reserves to fund its operations and development activities, which limits immediate financial flexibility but is a standard requirement for generating future value in drug discovery. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that mathematically reflects the company's inability to generate profit from sales or operations due to the current lack of substantial revenue streams. On the balance sheet, the company holds $341.92 million in cash against $23.31 million in debt, resulting in a debt-to-equity ratio of 6.57, which suggests a leveraged position typical for capital-intensive industries that prioritize asset growth over debt repayment. Despite the high debt-to-equity leverage, the current ratio of 15.50 demonstrates exceptional short-term liquidity, providing ample coverage for immediate obligations and operational needs. Furthermore, the return on equity is -47.5% and the return on assets is -28.0%, metrics that reveal that management is currently generating negative returns on invested capital as the company focuses resources on building the pipeline rather than maximizing immediate shareholder yield.
Evaluación de valoración
The trailing P/E ratio is listed as N/A due to the negative earnings, while the forward P/E is reported at -8.01, a metric that implies the market is pricing in a recovery in earnings or continued losses in the upcoming year rather than standard valuation multiples. The price-to-book ratio stands at 3.94, indicating that the stock is trading at a significant premium over its book value, which often reflects investor confidence in the potential value of the company's intangible assets and future drug approvals. The price-to-sales ratio is also N/A because there is no revenue to measure against the market price, and the EV/EBITDA is -7.76, suggesting that traditional valuation models based on earnings generation are not currently applicable to this asset. The stock has exhibited significant volatility over the past year, trading between a 52-week low of $6.71 and a high of $53.65, meaning the current price sits in a wide range relative to its historical extremes. The beta value is listed as N/A, preventing a direct comparison of price volatility against the broader market index, though the wide spread between the high and low suggests high idiosyncratic risk inherent in biotechnology equities.
Growth & Income
Revenue growth and earnings growth rates are both listed as N/A, as the company has not yet generated consistent commercial revenue streams to calculate year-over-year percentage changes. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, confirming that all available earnings, if any, or the majority of cash flow are being reinvested directly into research, development, and clinical trials rather than distributed to shareholders. This reinvestment strategy is characteristic of clinical stage biopharmaceutical companies that must prioritize long-term product development over immediate income distribution to investors. Consequently, the overall growth and income profile is defined entirely by the potential future commercialization of its drug candidates rather than current earnings expansion or dividend income, leaving investors exposed to the binary risks of clinical trial success without the cushion of current profitability.